The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
Open accessAbstract
BACKGROUND: Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial. METHODS: We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2.0 to 3.0) or aspirin (1300 mg per day) in a double-blind, multicenter clinical trial. The primary end point was ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke. RESULTS: After 569 patients had undergone randomization, enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive warfarin. During a mean follow-up period of 1.8 years, adverse events in the two groups included death (4.3 percent in the aspirin group vs. 9.7 percent in the warfarin group; hazard ratio for aspirin relative to warfarin, 0.46; 95 percent confidence interval, 0.23 to 0.90; P=0.02), major hemorrhage (3.2 percent vs. 8.3 percent, respectively; hazard ratio, 0.39; 95 percent confidence interval, 0.18 to 0.84; P=0.01), and myocardial infarction or sudden death (2.9 percent vs. 7.3 percent, respectively; hazard ratio, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.02). The rate of death from vascular causes was 3.2 percent in the aspirin group and 5.9 percent in the warfarin group (P=0.16); the rate of death from nonvascular causes was 1.1 percent and 3.8 percent, respectively (P=0.05). The primary end point occurred in 22.1 percent of the patients in the aspirin group and 21.8 percent of those in the warfarin group (hazard ratio, 1.04; 95 percent confidence interval, 0.73 to 1.48; P=0.83). CONCLUSIONS: Warfarin was associated with significantly higher rates of adverse events and provided no benefit over aspirin in this trial. Aspirin should be used in preference to warfarin for patients with intracranial arterial stenosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Benefit of Carotid Endarterectomy in Patients with Symptomatic Moderate or Severe Stenosis
Barnett, H. J. M., Taylor, D. W., Eliasziw, M., Fox, A. J., Ferguson, G. G., Haynes, R. B., Rankin, R. N., Clagett, G. P., Hachinski, V. C., Sackett, D. L., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811123392002 · Cited by 3,594
The Statistical Analysis of Failure Time Data
Klein, J. P. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,215
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
The Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Toole, J. F., Malinow, M. R., Chambless, L. E., Spence, J. D., Pettigrew, L. C., Howard, V. J., Sides, E. G., Wang, C.-H., & Stampfer, M. (2004) · JAMA · doi:10.1001/jama.291.5.565 · Cited by 1,391
WALKER, M. D., Marler, J. R., Goldstein, M., Grady, P. A., Toole, J. F., Baker, W. H., Castaldo, J., Chambless, L. E., Moore, W. S., Robertson, J. T., et al. (1995) · JAMA · doi:10.1001/jama.273.18.1421 · Cited by 1,334
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke
Mohr, J. P., Thompson, J. L. P., Lazar, R. M., Levin, B., Sacco, R. L., Furie, K. L., Kistler, J. P., Albers, G. W., Pettigrew, L. C., Adams, H. P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011258 · Cited by 1,168
Sacco, R. L., Kargman, D. E., Gu, Q., & Zamanillo, M. C. (1995) · Stroke · doi:10.1161/01.str.26.1.14 · Cited by 974
A standardized method for measuring intracranial arterial stenosis.
Samuels, O. B., Joseph, G., Lynn, M., Smith, H. A., & Chimowitz, M. I. (2000) · PubMed Central · Cited by 951
Self-citationWarfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
Broderick, J., Brott, T., Kothari, R., Miller, R., Khoury, J., Pancioli, A., Gebel, J., Mills, D., Minneci, L., & Shukla, R. (1998) · Stroke · doi:10.1161/01.str.29.2.415 · Cited by 752
The Warfarin-Aspirin Symptomatic Intracranial Disease Study
Chimowitz, M. I., Kokkinos, J., Strong, J., Brown, M. B., Levine, S. R., Silliman, S., Pessin, M. S., Weichel, E., Sila, C. A., Furlan, A. J., et al. (1995) · Neurology · doi:10.1212/wnl.45.8.1488 · Cited by 621
Self-citationInterim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Oral Anticoagulants and Intracranial Hemorrhage: Facts and Hypotheses
Hart, R. G., Boop, B. S., & Anderson, D. C. (1995) · Stroke · doi:10.1161/01.str.26.8.1471 · Cited by 541
Race and Sex Differences in the Distribution of Cerebral Atherosclerosis
Wityk, R. J., Lehman, D., Klag, M., Coresh, J., Ahn, H., & Litt, B. (1996) · Stroke · doi:10.1161/01.str.27.11.1974 · Cited by 518
van Es, R. F., Jonker, J. J., Verheugt, F. W., Deckers, J. W., & Grobbee, D. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09409-6 · Cited by 423
Development of aspirin resistance in persons with previous ischemic stroke.
Helgason, C. M., Bolin, K. M., Hoff, J. A., Winkler, S. R., Mangat, A., Tortorice, K. L., & Brace, L. D. (1994) · Stroke · doi:10.1161/01.str.25.12.2331 · Cited by 408
Chinese‐white differences in the distribution of occlusive cerebrovascular disease
Feldmann, E., Daneault, N., Kwan, E., Ho, K. J., Pessin, M. S., Langenberg, P., & Caplan, L. R. (1990) · Neurology · doi:10.1212/wnl.40.10.1540 · Cited by 356
Gage, B. F. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530230025025 · Cited by 329
The B-Value: A Tool for Monitoring Data
Lan, K. K. G., & Wittes, J. (1988) · Biometrics · doi:10.2307/2531870 · Cited by 303
Antithrombotic Therapy in Atrial Fibrillation
Laupacis, A., Albers, G., Dalen, J., Dunn, M. I., Jacobson, A. K., & Singer, D. E. (1998) · Chest · doi:10.1378/chest.114.5_supplement.579s · Cited by 294
Symptomatic intracranial atherosclerosis: Outcome of patients who fail antithrombotic therapy
Thijs, V. N., & Albers, G. W. (2000) · Neurology · doi:10.1212/wnl.55.4.490 · Cited by 284
Prognosis of Patients With Symptomatic Vertebral or Basilar Artery Stenosis
(1998) · Stroke · doi:10.1161/01.str.29.7.1389 · Cited by 256
Gorelick, P. B. (2003) · JAMA · doi:10.1001/jama.289.22.2947 · Cited by 241
Johnston, S. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp020891 · Cited by 207
Antiplatelet Effect of Aspirin in Patients With Cerebrovascular Disease
Alberts, M. J., Bergman, D. L., Molner, E., Jovanovic, B. D., Ushiwata, I., & Teruya, J. (2004) · Stroke · doi:10.1161/01.str.0000106763.46123.f6 · Cited by 180
Kharbanda, R. K., Walton, B., Allen, M., Klein, N., Hingorani, A. D., MacAllister, R. J., & Vallance, P. (2002) · Circulation · doi:10.1161/01.cir.0000017863.52347.6c · Cited by 172
High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation.
Ratnatunga, C., Edmondson, S. F., Rees, G. M., & Kovács, I. B. (1992) · Circulation · doi:10.1161/01.cir.85.3.1077 · Cited by 150
(2003) · Neuroepidemiology · doi:10.1159/000068744 · Cited by 126
Warfarin, aspirin, or both after myocardial infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J. E., & Arnesen, H. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00990-x · Cited by 106
Best treatment for intracranial arterial stenosis? 50 years of uncertainty
Benesch, C. G., & Chimowitz, M. I. (2000) · Neurology · doi:10.1212/wnl.55.4.465 · Cited by 66
Self-citationChan, A. T. (2003) · Cancer Causes & Control · doi:10.1023/a:1024986220526 · Cited by 42
Antiphospholipid Antibodies and Risk for Recurrent Vascular Events—Reply
Levine, S. R., Brey, R. L., Tilley, B. C., Triplett, D. A., Thompson, J. L. P., Sacco, R. L., Mohr, J. P., & for the APASS Investigators, F. T. A. I. (2004) · JAMA · doi:10.1001/jama.291.22.2702 · Cited by 35
Self-citationDiarrhoea associated with Clostridium difficile in AIDS patients receiving rifabutin
McBride, M., Coker, R., Horner, P., Weston, R., & Weber, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91252-1 · Cited by 18
Antiplatelet Drugs in Ischemic Stroke Prevention: From Monotherapy to Combined Treatment
Urbano, L. A., & Bogousslavsky, J. (2003) · Cerebrovascular Diseases · doi:10.1159/000074800 · Cited by 9
Cited by
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Self-citationKleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Self-citation
Metadata
- Authors
- Chimowitz, M. I., Lynn, M. J., Howlett-Smith, H., Stern, B. J., Hertzberg, V. S., Frankel, M. R., Levine, S. R., Chaturvedi, S., Kasner, S. E., Benesch, C. G., Sila, C. A., Jovin, T. G., & Romano, J. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-31
- Volume
- 352
- Issue
- 13
- Pages
- 1305-1316
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167806412
- Cited by
- 1,744
- References
- 39
- FWCI
- 68.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.